Clinical Research Directory

Inclusion Criteria: * Advanced solid tumors; * Measurable disease, per RECIST v1.1; * Eastern Cooperative Oncology Group (ECOG) performance status 0-1; * Adequate organ function; * Recover from all reversible AEs from previous anti-tumor treatment (i.e., Grade ≤ 1, according to NCI-CTCAE v5.0), excluding alopecia (any grade) and Grade ≤ 2 neuropathy peripheral; Exclusion Criteria: * Previous treatment with drugs targeting CLDN6 (including ADCs), or any drug containing topoisomerase I inhibitors (including ADCs); * Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 2 weeks with small molecule and within 4 weeks with biologic before the first dose of QLS5132; * Progressive or symptomatic brain metastases; * Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection; * History of significant cardiac disease, or poorly controlled diabetes mellitus; * History of recurrent autoimmune diseases; * History of myelodysplastic syndrome (MDS) or AML; * History of other active malignant tumors within 3 years before signing the informed consent form; * If female, is pregnant or breastfeeding; * Be allergic to any component of QLS5132 or its excipients.